TY - JOUR
T1 - Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer
AU - Ademuyiwa, Foluso O.
AU - Miller, Kathy D.
N1 - Funding Information:
Kathy D. Miller is supported in part by the Breast Cancer Research Foundation.
PY - 2008
Y1 - 2008
N2 - Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.
AB - Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.
KW - Bevacizumab
KW - Pazopanib
KW - Tamoxifen
KW - Tyrosine kinase inhibitors
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=60849136361&partnerID=8YFLogxK
U2 - 10.3816/CBC.2008.s.011
DO - 10.3816/CBC.2008.s.011
M3 - Article
C2 - 19158035
AN - SCOPUS:60849136361
VL - 8
SP - S151-S156
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - SUPPL. 4
ER -